1 - This article illustrates how much remains to be learned about degenerative brain diseases.
2 - This article illustrates that PBT2, by itself, may not be the only way to treat such diseases, and it is probably not a "magic bullet".
3 - This article illustrates the possibility of using a dual approach to treating such diseases: Use an MPAC compound to restore and maintain proper metals homeostasis, in combination with using the approach described in the article to prevent cell death.
I do not think it illustrates how much remains to be lerned about degenerative brain diseases. It's target was totally very different than to measure knowledge. It produced only one small piece of it. But it is a a paper among thousands of other papers and the value of it will be very big or very small, who knows. Every month there are already hundreds of papers about neurodegeneration and this is one of them.
It does not illustrate anything about PBT2 but it illustrates that misfolding of a protein (what is already known) is one step in neurodegeneration and also something more about cell death. Even from the works of Susan Lindquist (December 2011) we already know that PBT2 prevents this misfolding to happen. Different MPACs in Prana's portfolio have similar effects in these deurodegenerative disease, preventing misfolding, demonstrated by Linquist. A couple of days ago I posted a study demonstrating how the metals on atomistic level cause misfolding.
This paper does not give any "dual approach" possibility about MPAC and something else to prevent cell death. It is already known that PBT2 prevents cell death ( many papers, an example the mouse study over 1 y ago), but PBT2 treatment also demonstrated regrowth of the neural structures. It is much more than just explaining cell death as was done in this study. But best of all PBT2 did not only prevent the death of neurons in the brain but improved cognition. That means that the neurons started to work as they had been doing before the degenerative process. It would be wonderful if one day there would be a new compound which would improve the effect of PBT2 but I do not think this article has nothing to with improving the cognition improving effect of PBT2.
However it is an interesting paper and published in a top journal. It may one day be much more than what I can value it today from the point of Prana investor. This is only my opinion.
>> I do not think it illustrates how much remains to be lerned about degenerative brain diseases. <<
Really? Do you think we already fully understand neurodegenerative diseases? Do you think that the finding of the "switch" that controls brain-cell death is not a significant piece of new knowledge?
>> It does not illustrate anything about PBT2 <<
I agree. But it does illustrate that other approaches besides MPAC may have therapeutic benefit. We Prana shareholders are often tempted to assume that PBT2 is the be-all and end-all of Alzheimer's drugs, and that no competing approaches to treating the disease will ever become viable. The fact that someone has discovered a completely different way to precent cell death serves as an illustration that we must not remain so narrow-minded.
>> This paper does not give any "dual approach" possibility about MPAC and something else to prevent cell death. It is already known that PBT2 prevents cell death... <<
But do we know that PBT2 will be 100% effective at preventing cell death in humans? No, we don't. Again, I think it's important to keep an open mind about these things rather than to assume that PBT2 will be some sort of magic bullet that will, by itself, end Alzheimer's once and for all.